In short
Tabelecleucel, also known as ATA129, is an innovative cell therapy being studied in clinical trials for the treatment of various Epstein-Barr virus (EBV) associated diseases. This article explores the ongoing research on tabelecleucel, focusing on its potential benefits for patients with EBV-related conditions, particularly those who have not responded to standard treatments.
At a glance
- Drug Name
- Tabelecleucel (ATA129)
- Type of Therapy
- Allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Target Conditions
- EBV-associated post-transplant lymphoproliferative disease (PTLD), CNS PTLD, primary immunodeficiency LPD, acquired immunodeficiency LPD, EBV+ sarcomas
- Administration
- Intravenous infusion on days 1, 8, and 15 of each 35-day cycle
- Primary Endpoint
- Objective response rate (ORR)
- Secondary Endpoints
- Overall survival, duration of response, progression-free survival
- Key Inclusion Criteria
- EBV+ disease, failure of or ineligibility for standard therapies, measurable disease
- Key Exclusion Criteria
- Active infections, need for vasopressor or ventilatory support, recent use of certain therapies
- Trial Phase
- Phase 2 and Phase 3
What is Tabelecleucel?
Tabelecleucel, also known as ATA129 or Ebvallo, is an innovative cell therapy medication designed to treat various diseases associated with the Epstein-Barr virus (EBV). It is classified as an advanced therapy medicinal product, specifically a somatic cell therapy. Tabelecleucel consists of allogeneic (donor-derived) EBV-specific cytotoxic T lymphocytes, which are a type of immune cell programmed to target and destroy EBV-infected cells in the body.
What Conditions Does Tabelecleucel Treat?
Tabelecleucel is being investigated for the treatment of several EBV-associated diseases, including:
- Post-transplant lymphoproliferative disease (PTLD): A serious complication that can occur after organ or stem cell transplantation
- EBV-associated central nervous system PTLD (EBV+ CNS PTLD): PTLD affecting the brain and spinal cord
- EBV-associated primary immunodeficiency lymphoproliferative disease (EBV+ PID LPD): A condition occurring in individuals with inherited immune system defects
- EBV-associated lymphoproliferative disease in acquired immunodeficiency (EBV+ AID LPD): A condition occurring in individuals with weakened immune systems due to other factors
- EBV-associated sarcomas: Including leiomyosarcoma and other smooth muscle tumors
How Does Tabelecleucel Work?
Tabelecleucel works by introducing EBV-specific cytotoxic T lymphocytes into the patient's body. These specialized immune cells are designed to recognize and attack cells infected with the Epstein-Barr virus. By targeting EBV-infected cells, tabelecleucel helps to control the growth of EBV-associated tumors and reduce the symptoms of EBV-related diseases.
How is Tabelecleucel Administered?
Tabelecleucel is administered as an intravenous infusion. The treatment is typically given in cycles, with each cycle lasting 5 weeks (35 days). During a treatment cycle, patients receive tabelecleucel on days 1, 8, and 15. The maximum daily dose is 2 million organisms, with a maximum total dose of 36 million organisms over the course of treatment.
Current Clinical Trials
There are ongoing clinical trials evaluating the safety and efficacy of tabelecleucel:
- The ALLELE Study: A phase 3 trial for patients with EBV-associated PTLD after solid organ or allogeneic hematopoietic cell transplant who have failed prior treatments.
- The EBVision Study: A phase 2 trial investigating tabelecleucel in patients with various EBV-associated diseases, including those who are not eligible for standard treatments.
Efficacy of Tabelecleucel
The primary measure of tabelecleucel's effectiveness in clinical trials is the objective response rate (ORR), which includes complete responses (CR) and partial responses (PR) to treatment. Secondary measures include:
- Duration of response (DOR)
- Overall survival (OS)
- Progression-free survival (PFS)
- Time to response
- Graft status (for transplant patients)
The results of these trials will provide important information about how well tabelecleucel works in treating various EBV-associated diseases.
Safety and Side Effects
As with any medical treatment, tabelecleucel may cause side effects. The ongoing clinical trials are carefully monitoring patients for any adverse reactions. Some potential concerns include:
- Infections
- Graft-versus-host disease (for transplant patients)
- Immune system reactions
Patients receiving tabelecleucel are closely monitored during and after treatment to ensure their safety.
Patient Eligibility for Tabelecleucel Treatment
Eligibility for tabelecleucel treatment varies depending on the specific condition being treated. Generally, patients must have:
- A confirmed diagnosis of an EBV-associated disease
- Failed or been ineligible for standard treatments (in some cases)
- Adequate organ function
- No active, serious infections
- No recent treatment with certain other therapies that could interfere with tabelecleucel
Specific eligibility criteria may vary between different clinical trials and treatment protocols. Patients should consult with their healthcare providers to determine if tabelecleucel might be an appropriate treatment option for their condition.